Free Antibody Validation: Boster Bio Launches New Service to Advance Research Reproducibility
Pleasanton, May 29, 2025 (GLOBE NEWSWIRE) — Pleasanton, California –
With Boster Bio's latest promotion, scientists globally enjoy free access to antibody validation to boost research accuracy.
Boster Biological Technology, a leading provider of high-quality antibodies and ELISA kits, has announced a new promotion offering free antibody validation for its PicoBand antibody line. This initiative is designed to help scientists worldwide enhance research reliability by eliminating guesswork in antibody selection, allowing researchers to verify antibody specificity before purchase.
The PicoBand product line includes ultra-sensitive antibodies optimized for Western blotting (WB), immunohistochemistry (IHC), flow cytometry, and other key applications. Through this free Picoband antibody validation program, researchers can receive validation data for their antibody of interest, improving reproducibility in life sciences research.
'For decades, scientists have been forced to gamble on antibodies that might not work, leading to a waste of time, money, and resources. With our free PicoBand validation program, we're flipping the script. Not only can researchers now verify antibody performance before they commit, but submitting a request takes only two minutes and saves researchers days in lab work,' said CJ Xia, founder of Boster Bio.
Antibodies are critical tools in biomedical research, but inconsistent quality and lack of validation have led to reproducibility challenges. Boster Bio's free antibody validation program addresses this issue by providing documented proof of antibody performance without expending time and resources in the lab. Each batch undergoes strict quality control and is presented in detailed datasheets with experimental results.
Boster Bio's validation service addresses a longstanding industry issue—the inconsistent quality of antibodies. Researchers can choose from over 8,000 PicoBand antibodies, with the option to request validation on over 500 sample types, including human, mouse, rat, monkey, and zebrafish. Each antibody undergoes multi-application validation, covering WB, IHC, IF, ELISA, flow cytometry, and immunoprecipitation to ensure compatibility with diverse experimental needs.
This initiative underscores Boster Bio's commitment to transparency, accountability, and reproducibility in life sciences research, reinforcing its position as an innovator in reliable antibody production. Unlike typical vendors, Boster Bio's no-strings-attached policy allows researchers to verify performance data upfront, eliminating guesswork and costly trial-and-error purchases.
For more information, visit the website at https://www.bosterbio.com/
Founded in 1993, Boster Biological Technology has built a reputation for high-affinity antibodies, ELISA kits, and protein analysis tools, products widely used globally in academic, pharmaceutical, and biotech research. Promoting the free antibody validation aligns with Boster Bio's mission to support the scientific community with dependable reagents, providing clients with antibody validation before purchase.
For decades, scientists have been forced to gamble hundreds or thousands of dollars on antibodies that might not even work and had to rely on reputation, citations, and gut instinct to pick reagents, resulting in unreliable data, weeks of wasted time, and little support.
'At Boster Bio, our mission is to move the antibody industry into its next stage. We're not offering a free sample, but starting a movement. It's a fundamental rethinking of what it means to support scientific discovery. When vendors take responsibility for antibody performance upfront, scientists can focus on what matters most—discovery,' added Xia.
This initiative underscores the company's commitment to transparency and reproducibility in life sciences. By providing free Picoband antibody validation, Boster Bio empowers labs to conduct experiments confidently, reducing wasted resources and accelerating discoveries. Scientists worldwide can leverage this program to access high-affinity, batch-consistent antibodies backed by documented proof of specificity.
Specializing in antibodies, ELISA kits, and protein research tools, Boster Biological Technology is committed to delivering high-quality products. With the recent unveiling of its manifesto for antibody accountability, Boster Bio is offering free antibody validation services to meet the client's experiment settings. More than just a promotion, this program is designed to raise industry standards, redefining how antibodies are evaluated and adopted to ensure continued scientific rigor and customer success.
About the Company:
Boster Biological Technology is a global leader in antibody production and immunoassay solutions, serving academic, pharmaceutical, and biotech researchers. Based in Pleasanton, CA, the company contributes significantly to accelerating scientific discovery through innovative reagents and exceptional service. Boster Bio is committed to transparency and reproducibility, offering free antibody validation in WB, IHC, IF, flow cytometry, IP, and ELISA, ensuring researchers receive fully characterized reagents.
###
For more information about Boster Biological Technology, contact the company here:
Boster Biological TechnologyCJ Xia(888) 466-3604
[email protected]
3942 Valley Ave, Pleasanton, CA 94566, USA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Extendicare Acquires Nine Long-Term Care Homes from Revera
MARKHAM, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. ('Extendicare') (TSX: announced today that, effective June 1, 2025, it has completed the previously announced transaction with Revera Inc. and certain of its affiliates to acquire nine 'Class C' long-term care homes (the 'Acquired Homes') located in Ontario and Manitoba and one parcel of vacant land located in Ontario (the 'Transaction'). The consideration for the Transaction was approximately $60.3 million, comprised of $40.2 million in cash and the assumption of certain liabilities of $20.1 million, including government funding reimbursement obligations and committed capital maintenance project obligations, excluding transaction costs. The purchase price was funded from cash on hand. The Acquired Homes are set out in the table below. Name Address LTC Beds(1) Retirement Beds Blenheim Community Village Blenheim, ON 57 30 Brierwood Gardens Brantford, ON 67 71 Riverbend Place Cambridge, ON 39 92 Summit Place Owen Sound, ON 99 77 Telfer Place Paris, ON 35 180 Village on the Ridge Ridgetown, ON 30 65 Trillium Court Kincardine, ON 34 59 Carlingview Manor(2) Ottawa, ON 250 – Poseidon Winnipeg, MB 211 – Total beds 822 574 (1) LTC beds excludes 133 third and fourth ward-style beds that have been taken out of service per regulatory requirements that are eligible to be reinstated upon redevelopment. (2) Carlingview Manor is in the process of being redeveloped into a new 320-bed LTC home that is owned by the joint venture between Extendicare and Axium. About Extendicare Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of a growing seniors' population, inspired by our mission to provide people with the care they need, wherever they call home. We operate a network of 99 long-term care homes (59 owned, 40 under management contracts), deliver approximately 11.2 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 148,200 beds across Canada. Extendicare proudly employs approximately 26,500 qualified, highly trained and dedicated team members who are passionate about providing high-quality care and services to help people live better. For further information, please contact: Investor Inquiries: David BaconExecutive Vice President and Chief Financial OfficerEmail: Phone: (905) 470-4000Sign in to access your portfolio
Business Upturn
an hour ago
- Business Upturn
Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) as a single agent or in combination with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (ACC) or other solid tumors in a poster presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. Alrizomadlin is the first MDM2-p53 inhibitor to enter clinical development in China and a key investigational drug candidate in Ascentage Pharma's apoptosis-targeted pipeline with global first-in-class potential. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. Returning to the ASCO Annual Meeting for the eighth consecutive year, Ascentage Pharma has garnered growing interest from the global research community. This year, two studies of the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin, key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation, at the ASCO Annual Meeting. These clinical data on alrizomadlin in ACC and other solid tumors demonstrated the antitumor activity of alrizomadlin monotherapy in patients with advanced ACC or malignant peripheral nerve sheath tumor (MPNST). Moreover, alrizomadlin in combination with toripalimab was well tolerated and showed therapeutic potential in MPNST, biliary-tract cancer (BTC), and liposarcoma (LPS). Prof. Ye Guo, MD, a Principal Investigator of the study from the Department of Medical Oncology, Shanghai East Hospital, noted, 'ACC is a rare cancer type that lacks effective treatment options, and the treatment with antiangiogenic tyrosine kinase inhibitors faces certain limitations and safety concerns. At ASCO 2025, our team presented data of alrizomadlin in patients with ACC that demonstrated an objective response rate (ORR) of 16.7% and a disease control rate (DCR) of 100%. These results suggest that the targeted inhibition of the MDM2-p53 pathway has antitumor activity in ACC; therefore, it can potentially offer a new treatment strategy to patients with ACC.' Prof. Ning Li, MD, a Principal Investigator of the study from the Chinese Academy of Medical Sciences Cancer Hospital, commented, 'Currently, there are limited treatment options for patients with sarcomas such as MPNST and LPS. In this study, alrizomadlin both as a monotherapy and in combination with a PD-1 therapy, showed favorable antitumor activity in MPNST. The clinical benefit was particularly notable in patients who received the combination regimen, with two patients with MPNST achieving long-term responses that lasted more than 60 and 96 weeks, respectively. Furthermore, alrizomadlin in combination with a PD-1 therapy also showed clinical activity in LPS. These results suggest that alrizomadlin monotherapy and combination regimens may bring clinical benefit to more patients with sarcoma.' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Alrizomadlin is an investigational drug with global first-in-class potential. The clinical data presented at this year's ASCO Annual Meeting demonstrated the therapeutic potential of alrizomadlin, both as a monotherapy and in combinations, in ACC and other solid tumors, and underscored the synergistic effects between alrizomadlin and immunotherapies, thus suggesting a promising therapeutic strategy for various solid tumors. We are focused on addressing unmet clinical needs in China and around the world, and intend to further accelerate our clinical programs to advance more novel treatment options for patients as soon as possible.' Highlights of this abstract selected for presentation at ASCO 2025 are as follows: A Phase 2 Study of Novel MDM2 Inhibitor Alrizomadlin (APG-115) With or Without Toripalimab in Patients with Advanced Adenoid Cystic Carcinoma (ACC) or Other Solid Tumors Abstract #: 6102 6102 Format: Poster Presentation Poster Presentation Session Title: Head and Neck Cancer Head and Neck Cancer Principal Authors: Ye Guo, MD, Department of Medical Oncology, Shanghai East Hospital, China; Ning Li, MD, Chinese Academy of Medical Sciences Cancer Hospital, China; Xing Zhang, MD, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; Meiyu Fang, MD, Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, China; Shuhang Wang, MD, Chinese Academy of Medical Sciences Cancer Hospital, China, et al. Ye Guo, MD, Department of Medical Oncology, Shanghai East Hospital, China; Ning Li, MD, Chinese Academy of Medical Sciences Cancer Hospital, China; Xing Zhang, MD, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; Meiyu Fang, MD, Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, China; Shuhang Wang, MD, Chinese Academy of Medical Sciences Cancer Hospital, China, et al. Highlights: Alrizomadlin is a novel investigational oral MDM2 inhibitor that has shown a manageable safety profile with initial clinical activity in ACC. As of the data cutoff date of February 13, 2025, 57 patients with advanced ACC, malignant peripheral nerve sheath tumor (MPNST), liposarcoma (LPS), biliary-tract cancer (BTC), and other tumors were enrolled. Alrizomadlin monotherapy showed encouraging antitumor activity in patients with advanced ACC or MPNST. Alrizomadlin in combination with toripalimab was also well tolerated and demonstrated antitumor activity in patients with MPNST, BTC, and LPS. In the monotherapy arm, 17 patients were efficacy-evaluable. The ORR was 16.7%, and the DCR was 100% in 12 patients with ACC. The DCR was 80% in 5 patients with MPNST, 4 of whom achieved stable disease (SD). In 24 safety-evaluable patients, 33.3% reported grade 3 or higher treatment-related adverse events (TRAEs). Three patients (12.5%) experienced treatment-related serious adverse events (SAEs). One patient discontinued treatment because of TRAE. In the combination arm, 29 patients were efficacy-evaluable. The ORR was 16.7% and the DCR was 100% in 6 patients with BTC. The ORR was also 16.7% and the DCR was 66.7% in 6 patients with LPS. Two patients with MPNST had confirmed partial response (PR) with prolonged progression free survival (PFS) of 60 + weeks and 96 + weeks, respectively. In 27 safety-evaluable patients treated with alrizomadlin at the 150 mg dose level, 12 (44.4%) experienced grade 3 or higher TRAEs. Treatment-related SAEs were reported in 8 patients (29.6%). One patient discontinued treatment because of TRAE. * Alrizomadlin (APG-115) is an investigational compound and has not been approved by the US FDA. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations:Hogan Wan, Head of IR and StrategyAscentage Pharma [email protected] +86 512 85557777
Business Upturn
an hour ago
- Business Upturn
Nimanode Positions To Become The OpenSea of AI Agents On XRP Blockchain
By GlobeNewswire Published on June 3, 2025, 02:34 IST LEEDS, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) — Excitement is building across the XRP community as Nimanode ($NMA) , the first AI agent platform on the XRP Ledger, positions itself as the premier destination for intelligent automation within the Ripple ecosystem. Amid growing bullish sentiment around XRP — driven by XRP Futures trading going live seasoned investors from major ecosystems like Cardano ($ADA) and Solana ($SOL), are turning their attention to the Nimanode Presale , eager to secure early exposure to what many see as a foundational layer for on-chain AI infrastructure. Pioneering AI Agents on XRP Nimanode is strategically emerging as the leading marketplace and launch platform for autonomous AI agents on the XRP Ledger. Just as OpenSea redefined digital ownership through NFTs, Nimanode is redefining utility through AI agents that work, evolve, and earn on-chain. Designed specifically to offer a no-code gateway to intelligent, on-chain automation at scale. Nimanode offers services from solo builders to enterprises — to deploy intelligent agents that automate smart contracts, optimize DeFi strategies, assess protocol risk, and manage tokenized real-world assets (RWAs). This transformative model brings a new dimension to DeFi and AI adoption in the XRP ecosystem, by combining modular AI technology with XRPL's unmatched speed and low transaction costs, opening up a new era of AI x Blockchain, with real monetization potential built into every deployment. Join Nimanode Presale Why Investors are Flocking to The Nimanode Presale The presale surge has captured the attention of prominent crypto investors including notable whales from the BNB, ADA and SOL communities. All looking to position themselves early in what many believe could be the next DeFi breakout project. From the desk of the development team at Nimanode, they are set to deliver an Agentic workforce handling various tasks autonomously. Features of these ecosystem include but not limited to Zero-Code Agent Builder – Easily create and configure AI agents through a drag-and-drop interface Autonomous Execution – Agents perform on-chain tasks, react to data feeds, and interact across dApps Agent Marketplace – Build, deploy and monetize AI agents within a Nimanode ecosystem XRPL Integration – High-speed, low-cost, and eco-friendly infrastructure to power scalable agent activity $NMA Token – Powering the Nimanode Ecosystem The native $NMA token is the backbone of the Nimanode platform, unlocking utility and benefits across their ecosystem through: Agent Deployment : Lower fees for launching and customizing AI agents. : Lower fees for launching and customizing AI agents. Staking Rewards : Earn passive income by staking $NMA tokens. : Earn passive income by staking $NMA tokens. Marketplace Access : Use $NMA to buy, license, or upgrade agents. : Use $NMA to buy, license, or upgrade agents. Governance: Participate in DAO proposals and help shape platform evolution. At the end of the presale, $NMA will list on DEXs at a 25% higher price, offering early participants immediate upside on their investments. How to Join The Nimanode Presale Joining in the NimaNode Presale is quite straightforward for anyone seasoned investors and newbies alike. Setup an XRP-Compatible Wallet: Ensure you have a non-custodial wallet capable of receiving XRP native tokens like Xaman Wallet. Purchase XRP: Acquire XRP from reputable exchanges like Binance, Coinbase, or Bybit. Participate in the Presale: Visit the NimaNode presale page ( ), send your XRP to the provided presale address, and secure your $NMA tokens. The last cycle gave us DeFi protocols and NFTs. This cycle is shaping up to be about autonomous infrastructure and Nimanode is at the heart of it. Don't Miss Out – Secure your $NMA Tokens Learn more about Nimanode Website: Twitter/X: Telegram: Whitepaper: Contact:Nick Lambert [email protected] Disclaimer : This is a paid post and is provided by Nimanode. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
